Pengaruh Rasio Doxorubisin:Apoferritin terhadap Kapasitas dan Efisiensi Enkapsulasi Doksorubisin dalam Apoferritin

Novita Wiwoho(1*), Maria Christina Prihatiningsih(2), Mujamilah Mujamilah(3), Grace Tj. Sulungbudi(4)

(1) Sekolah Tinggi Teknologi Nuklir
(2) Sekolah Tinggi Teknologi Nuklir-BATAN, Babarsari, Yogyakarta
(3) Pusat Sains dan Teknologi Bahan Maju-BATAN, Kawasan Puspiptek Serpong, Tangerang Selatan
(4) Pusat Sains dan Teknologi Bahan Maju-BATAN, Kawasan Puspiptek Serpong, Tangerang Selatan
(*) Corresponding Author


Doxorubicin is a chemotherapy drug which is very toxic and causes many side effects. To reduce side effects, doxorubicin can be encapsulated by apoferritin into apoferritin doxorubicin (Apo-Dox) system. In this research, various mass of doxorubicin i.e. 0.17 mg (S1), 0.26 mg (S2), 0.35 mg (S3), and 0.52 mg (S4) were encapsulated with 21.50 mg apoferritin. Encapsulation process was carried out by lowering pH medium for apoferritin dis-assembly, doxorubicin addition and dialysis for gradual and controlled pH-increase of medium to support re-assembly of apoferritin and doxorubicin encapsulation. End-result samples were then centrifuged and washed to separate the unreacted doxorubicin and apoferritin’s subunits. Doxorubicin encapsulation efficiency was determined using microplate reader spectrophotometry. The highest encapsulation capasity was 3.87 g dox/mg apo for S4 samples. Increasing the weight of doxorubicin gives more significant effect on increasing the reactive weight of apoferritin, which reached 93.73% (S4 sample). Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) analysis confirm that apoferritin is in the Apo-Dox sample.



Doksorubisin merupakan obat kemoterapi yang sangat toksik dan menimbulkan berbagai efek samping. Untuk mengurangi efek samping tersebut, doksorubisin dapat dibungkus dengan protein apoferritin menjadi Apoferritin-Doksorubisin (Apo-Dox). Dalam penelitian ini, doksorubisin dengan berat 0,174 mg (S1), 0,261 mg (S2), 0,349 mg (S3), dan 0,523 mg (S4) dienkapsulasi apoferritin dengan berat 21,487 mg. Proses enkapsulasi dilakukan dengan mengubah pH larutan melalui penambahan glisin asetat, tris base, dan dialisa dalam tris asetat. Larutan di centrifuge dan di cuci untuk menghilangkan doksorubisin dan sub-unit apoferritin yang tidak bereaksi. Konsentrasi doksorubisin yang terenkapsulasi dalam apoferritin (μg dox/mg apo) ditentukan menggunakan microplate reader spectrophotometry. Konsentrasi cenderung mencapai optimum mulai sampel S2 dan hanya sedikit meningkat untuk sampel S3 dan S4 dengan nilai maksimum pada S4 sebesar 3,87 μg dox/mg apo. Peningkatan jumlah doksorubisin akan meningkatkan jumlah apoferritin yang bereaksi, dan diperoleh nilai efisiensi reaksi apoferritin tertinggi 93,73% untuk sampel S4. SDS-PAGE membuktikan bahwa apoferritin berada pada sampel Apo-Dox.


Enkapsulasi; doksorubisin; protein apoferritin; Apo-Dox


Carvalho, C., Santos, R., Cardoso, S., Correia, S., Oliveira, P., Santos, M., & Moreira, P., 2009,. Doxorubicin: The Good, the Bad and the Ugly Effect. Current Medicinal Chemistry, 16(25), 3267–3285.

Crichton, R., 2009, Iron Metabolism-From Molecular Mechanisms to Clinical Consequences (Third Edition), John Wiley and Sons, Ltd., Singapore

Crichton, R. R., Millar, J. a, Cumming, R. L., & Bryce, C. F. (1973). The organ specificity of ferritin in human and horse liver and spleen. The Biochemical Journal, 131(1), 51–9.

Dostálová, S., Konečná, R., Blažková, I., Vaculovičová, M., Kopel, P., Křížková, S., Kizek, R., 2013, Apoferritin as A Targeted Drug Delivery System, 908–912.

Ganta, S., Devalapally, H., Shahiwala, A., & Amiji, M., 2008, A review of stimuli-responsive nanocarriers for drug and gene delivery, Journal of Controlled Release, 126(3), 187–204.

Heger, Z., Skalickova, S., Zitka, O., Adam, V., & Kizek, R., 2014, Apoferritin applications in nanomedicine. Nanomedicine (London, England), 9(14), 2233–45

Kilic, M. A., Ozlu, E., & Calis, S., 2012, A novel protein-based anticancer drug encapsulating nanosphere: Apoferritin-doxorubicin complex, Journal of Biomedical Nanotechnology, 8(3), 508–514.

Massover, W. H., 1993, Ultrastructure of ferritin and apoferritin: A review. Micron, 24(4), 389–437.

Mohan, P., & Rapoport, N., 2011, Doxorubicin as a molecular nanotheranostic agent: effect of doxorubicin encapsulation in micelles or nanoemulsions on the ultrasound mediated intracellular delivery and nuclear trafficking, 4(164), 1959–1973

Tacar, O., Sriamornsak, P., & Dass, C. R., 2012, Doxorubicin: An update on anticancer molecular action, toxicity and novel drug delivery systems. Journal of Pharmacy and Pharmacology, 65(2), 157–170.

Tmejova, K., Hynek, D., Kopel, P., Dostalova, S., Smerkova, K., Stanisavljevic, M., Adam, V., 2013, Electrochemical behaviour of doxorubicin encapsulated in apoferritin, International Journal of Electrochemical Science, 8(12), 12658–12671.


Article Metrics

Abstract views : 1939 | views : 2095


  • There are currently no refbacks.

Copyright (c) 2017 Jurnal Rekayasa Proses

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Jurnal Rekayasa Proses  (print ISSN 1978-287X; online ISSN 2549-1490) is published by Chemical Engineering Department, Faculty of Engineering, Universitas Gadjah Mada. View website statistics.